5. The method according to any one of claims 1 to 4, characterized in that the expression cassettes and the selection marker are arranged unidirectional.

6. The method according to any one of claims 1 to 5, characterized in that the expression cassettes are arranged in the sequence LC-HC-SM.

7. The method according to any one of claims 1 to 6, characterized in that the mammalian cell is selected from CHO cell, HEK cell, BHK cell, NS0 cell, and SP2/0 cell.

8. The method according to any one of claims 1 to 7, characterized in that the mammalian cell is a CHO cell for the selection of a stable transfected cell.

9. The method according to any one of claims 1 to 8, characterized in that the expression vector comprises either

- a first expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a first antibody light chain, a bGH polyA signal sequence, and a hGT terminator sequence,
- a second expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a second antibody light chain, a bGH polyA signal sequence, and a hGT terminator sequence,
- a third expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a first antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence,
- a fourth expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a second antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence,

or

- a first expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding an antibody light chain, a bGH polyA signal sequence, and a hGT terminator sequence,
- a second expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a first antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence, and
- a third expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a second antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence,

whereby the antibody light chain is a common light chain for both antibody heavy chains.

10. The method according to any one of claims 1 to 9, characterized in that expression vector is encoding a bispecific antibody.

11. The method according to any one of claims 9 to 10, characterized in that the bispecific antibody has a first binding specificity or binding site that specifically binds to a first antigen or a first epitope on an antigen and the bispecific antibody has a second binding specificity or binding site that specifically binds to a second antigen or second epitope on the antigen.

12. The method according to any one of claims 9 to 11, characterized in that the expression vector comprises

- an antibody light chain expression cassette,
- a first antibody heavy chain expression cassette,
- a second antibody heavy chain expression cassette, and
- a selection marker expression cassette.

13. The method according to any one of claims 9 to 12, characterized in that the expression vector comprises

- a first antibody light chain expression cassette,
- a second antibody light chain expression cassette,
- a first antibody heavy chain expression cassette,
- a second antibody heavy chain expression cassette, and
- a selection marker expression cassette.

14. The method according to any one of claims 9 to 13, characterized in that one of the antibody heavy chain expression cassettes encodes an antibody heavy chain comprising a hole mutation.

15. The method according to any one of claims 9 to 14, characterized in that one of the antibody heavy chain expression cassettes encodes an antibody heavy chain comprising a knob mutation.

16. The method according to any one of claims 9 to 15, characterized in that one of the antibody light chain expression cassettes encodes an antibody light chain variant comprising an antibody light chain variable domain and an antibody heavy chain CH1 domain as constant domain and/or one of the antibody light chain expression cassettes encodes an antibody light chain comprising an antibody light chain variable domain and an antibody light chain CL domain as constant domain.

17. The method according to any one of claims 9 to 16, characterized in that one of the antibody heavy chain expression cassettes encodes an antibody heavy chain variant comprising as first constant domain an antibody light chain constant domain (CL), and/or one of the antibody heavy chain expression cassettes encodes an antibody heavy chain comprising as first constant domain an antibody heavy chain CH1 domain

~~9~~18. A method for producing an antibody comprising the following steps:

a) cultivating a mammalian cell comprising

- a first expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding an antibody light chain, a bGH polyA signal sequence, and a hGT terminator sequence,

- a second expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding an antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence, and

b) recovering the antibody from the cell or the cultivation medium,

whereby the first expression cassette and the second expression cassette are arranged unidirectional for the stable production of the antibody.

~~10~~19. The method according to claim ~~9~~18, characterized in that the nucleic acid encoding the antibody light chain and/or the nucleic acid encoding the antibody heavy chain comprises at least one intron.

~~11~~20. The method according to any one of claims ~~9~~-18 to ~~10~~19, characterized in that the nucleic acid encoding the antibody light chain and/or the nucleic acid encoding the antibody heavy chain is cDNA.

~~12~~21. The method according to any one of claims ~~9–~~18 to ~~11~~20, characterized in that the expression plasmid further comprises a selection marker.

~~13~~22. The method according to any one of claims ~~9–~~18 to ~~12~~21, characterized in that the expression cassettes and the selection marker are arranged unidirectional.

~~14~~23. The method according to any one of claims ~~9–~~18 to ~~13~~22, characterized in that the expression cassettes are arranged in the sequence LC-HC-SM.

~~15~~24. The method according to any one of claims ~~9–~~18 to ~~14~~23, characterized in that the mammalian cell is selected from CHO cell, HEK cell, BHK cell, NS0 cell, and SP2/0 cell.

~~16~~25. The method according to any one of claims ~~9–~~18 to ~~15~~24, characterized in that the mammalian cell is a CHO cell for the stable production of an antibody.

~~17~~26. An expression vector comprising

- a first expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding an antibody light chain, a bGH polyA signal sequence, and a hGT terminator sequence,
- a second expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding an antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence.

~~18~~27. The expression vector according to claim ~~17~~26, characterized in that the nucleic acid encoding the antibody light chain and/or the nucleic acid encoding the antibody heavy chain comprises at least one intron.

~~19~~28. The expression vector according to any one of claims ~~17~~-26 to ~~18~~27, characterized in that the nucleic acid encoding the antibody light chain and/or the nucleic acid encoding the antibody heavy chain is cDNA.

~~20~~29. The expression vector according to any one of claims ~~17~~-26 to ~~19~~28, characterized in that the first expression cassette and the second expression cassette are arranged unidirectional for the selection of a stable transfected cell.

~~21~~30. The expression vector according to any one of claims ~~17~~-26 to ~~20~~29, characterized in that the expression plasmid further comprises a selection marker.

~~22~~31. The expression vector according to any one of claims ~~17~~-26 to ~~21~~30, characterized in that the expression cassettes and the selection marker are arranged unidirectional.

~~23~~32. The expression vector according to any one of claims ~~17~~-26 to ~~22~~31, characterized in that the expression cassettes are arranged in the sequence LC-HC-SM.

~~24~~33. The expression vector ~~or the method~~ according to any one of claims ~~1~~–26 to ~~23~~32, characterized in that the expression vector comprises either

- a first expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a first antibody light chain, a bGH polyA signal sequence, and a hGT terminator sequence,
- a second expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a second antibody light chain, a bGH polyA signal sequence, and a hGT terminator sequence,
- a third expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a first antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence,
- a fourth expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a second antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence,

or

- a first expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding an antibody light chain, a bGH polyA signal sequence, and a hGT terminator sequence,
- a second expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a first antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence, and
- a third expression cassette comprising in 5' to 3' direction a hCMV promoter, a nucleic acid encoding a second antibody heavy chain, a bGH polyA signal sequence, and a hGT terminator sequence,

whereby the antibody light chain is a common light chain for both antibody heavy chains.

~~25~~34. The expression vector ~~or the method~~ according to any one of claims ~~1~~–26 to ~~24~~33, characterized in that expression vector is encoding a bispecific antibody.

~~26~~35. The expression vector ~~or the method~~ according to any one of claims ~~24~~–33 to ~~25~~34, characterized in that the bispecific antibody has a first binding specificity or binding site that specifically binds to a first antigen or a first epitope on an antigen and the bispecific antibody has a second binding specificity or binding site that specifically binds to a second antigen or second epitope on the antigen.

~~27~~36. The expression vector ~~or the method~~ according to any one of claims ~~24~~–33 to ~~26~~35, characterized in that the expression vector comprises

- an antibody light chain expression cassette,
- a first antibody heavy chain expression cassette,
- a second antibody heavy chain expression cassette, and
- a selection marker expression cassette.

~~28~~37. The expression vector ~~or the method~~ according to any one of claims ~~24~~–33 to ~~27~~36, characterized in that the expression vector comprises

- a first antibody light chain expression cassette,
- a second antibody light chain expression cassette,
- a first antibody heavy chain expression cassette,
- a second antibody heavy chain expression cassette, and
- a selection marker expression cassette.

~~29~~38. The expression vector ~~or the method~~ according to any one of claims ~~24~~–33 to ~~28~~37, characterized in that one of the antibody heavy chain expression cassettes encodes an antibody heavy chain comprising a hole mutation.

~~30~~39. The expression vector ~~or the method~~ according to any one of claims ~~24~~–33 to ~~29~~38, characterized in that one of the antibody heavy chain expression cassettes encodes an antibody heavy chain comprising a knob mutation.

~~31~~40. The expression vector ~~or the method~~ according to any one of claims ~~24~~ 33 to ~~30~~39, characterized in that one of the antibody light chain expression cassettes encodes an antibody light chain variant comprising an antibody light chain variable domain and an antibody heavy chain CH1 domain as constant domain and/or one of the antibody light chain expression cassettes encodes an antibody light chain comprising an antibody light chain variable domain and an antibody light chain CL domain as constant domain.

~~32~~41. The expression vector ~~or the method~~ according to any one of claims ~~24~~ 33 to ~~31~~40, characterized in that one of the antibody heavy chain expression cassettes encodes an antibody heavy chain variant comprising as first constant domain an antibody light chain constant domain (CL), and/or one of the antibody heavy chain expression cassettes encodes an antibody heavy chain comprising as first constant domain an antibody heavy chain CH1 domain.